Authors
Latest:
Clinical Development of Cyclin-Dependent Kinase Inhibitors in Lung CancerThis manuscript focuses on the latest clinical developments of newer generation selective CDK inhibitors in lung cancer.
Latest:
Gene Removal May Pose Future Treatment in Advanced MelanomaDespite the availability of several new agents in the past 5 years for the treatment of melanoma, patients with advanced melanoma still suffer poor prognoses.
Latest:
Safety and Efficacy Results of Phase I/II SCOOP Trial in mCRCAkihito Kawazoe, MD, discussed the safety and efficacy results of the phase I/II SCOOP trial of napabucasin plus pembrolizumab for treatment of patients with metastatic colorectal cancer.
Latest:
Advice To Community Oncologists Treating Patients With CRCAl B. Benson III, MD, FACP, FASCO, professor of medicine at Northwestern University, shares advice to community oncologists treating patients with colorectal cancer. He emphasizes looking carefully at different patient characteristics before making treatment decisions.
Latest:
Liquid Biopsy Results Extend the Use of Tissue Samples in Lung CancerAlain Borczuk, MD, discusses the current role for liquid biopsies versus tissue biopsies in lung cancer and the challenges that need to be overcome in this space.
Latest:
Key Considerations When Selecting Frontline Therapy in mCRCAlan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses key considerations in the selection of frontline therapy in metastatic colorectal cancer.
Latest:
Follicular Lymphoma: Emerging TreatmentsAn oncologist ruminates on emerging treatment options in follicular lymphoma and offers some clinical pearls.
Latest:
Managing Patients With Chronic Lymphocytic LeukemiaAlessandra Ferrajoli, MD, discusses the importance of supportive care in the management of patients with chronic lymphocytic leukemia with comorbidities.
Latest:
Efficacy Results for Trastuzumab in HER2-Positive Uterine Serous CarcinomaAlessandro D. Santin, MD, a professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, discusses results of a randomized phase II trial of trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab (Herceptin) in advanced or recurrent uterine serous carcinomas that overexpress HER2/neu during the 2018 Society of Gynecologic Oncology Annual Meeting.
Latest:
Evaluating the Activity of Trabectedin and Radiotherapy in SarcomaAlessandro Gronchi, MD, discusses a phase 2 trial of trabectedin and radiotherapy in patients with soft-tissue sarcoma.
Latest:
From the Editor: PARP Inhibitors, Biomarker Research, and Gene EditingOur physician editor-in-chief highlights the February 2015 issue of The Journal of Targeted Therapies in Cancer.
Latest:
A Study of Brentuximab Vedotin and Nivolumab in Relapsed or Treatment-Resistant Hodgkin LymphomaAlex Herrera, MD, assistant professor, City of Hope, discusses a study investigating the use of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in the treatment of relapsed or treatment-resistant Hodgkin lymphoma during the American Society of Hematology (ASH) Annual Meeting.
Latest:
Phase II Trial Shows Antitumor Activity With Cemiplimab in mCSCCAlexander D. Guminski, MD, PhD, discusses the 12-month follow-up data from a phase II study investigating the role of cemiplimab as a treatment for patients with metastatic cutaneous squamous cell carcinoma.
Latest:
Drilon Explains Testing for NTRK Gene FusionsAlexander Drilon, MD, discusses what to know when testing for NTRK gene fusions in patients with lung cancer.
Latest:
Testing for NTRK Gene Fusions in the Community SettingAlexander Drilon, MD, discusses what community oncologists should know about testing for NTRK gene fusions in patients with solid tumors.
Latest:
Highlighting Latest Additions to the Treatment Landscape for AMLAlexander E. Perl, MD, discusses the latest advancements in the treatment landscape for patients with acute myeloid leukemia. These advances are driven by 2 factors: a better understanding of the biology of the disease and improving therapeutics to meet that understanding.
Latest:
HHLA2 Vs PD-L1 Expression in Urothelial TumorsAlexander I. Sankin, MD, assistant professor of Urology at Montefiore Medical Center at the Albert Einstein College of Medicine, discusses the differences between the recently defined checkpoint HHLA2 and PD-L1 expression in urothelial tumors, as well as next steps in this space.
Latest:
Dr. Alexander Kutikov on Options Afforded to Kidney Cancer PatientsKutikov points out that not every mass needs to be resected and that patients need to understand the risks associated with each decision they make in the treatment process.
Latest:
3-Year Update Shows Continued Efficacy of Pembrolizumab for MelanomaAlexander M. Eggermont, MD, PhD, discusses the results of the KEYNOTE 054 trial of pembrolizumab versus placebo in patients with high-risk stage III melanoma after a complete resection.
Latest:
Results of Pembrolizumab in High-Risk Stage III MelanomaAlexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the phase III results from the EORTC 1325-MG/KEYNOTE-054 trial presented at the 2018 AACR Annual Meeting.
Latest:
Challenges to Overcome With CAR T-Cell Therapy for Acute Myeloid LeukemiaAlexander Perl, MD, an associate professor of medicine at the University of Pennsylvania, discusses the current challenges with CAR T-cell therapy for the treatment of patients with acute myeloid leukemia
Latest:
Intra-Arterial Therapies for Hepatic MalignanciesThe researchers review intra-arterial therapies and the latest literature supporting their use, categorized by different tumor types.
Latest:
Efficacy of Onapristone in PR-Expressing TumorsAlexander Zukiwski, MD, CEO, Arno Therapeutics, Inc., discusses the efficacy of onapristone (ONA) in progesterone receptor (PR)-expressing tumors.
Latest:
Second-Line Immunotherapy Combos in MORPHEUS Trial for Advanced Urothelial CarcinomaAlexandra Drakaki, MD, assistant professor of medicine, hematology, and oncology, University of California, Los Angeles, discusses the goals of the phase Ib/II MORPHEUS trial, which is an umbrella study evaluating several second-line immunotherapy combinations in patients with advanced or metastatic urothelial carcinoma.
Latest:
The Promise of Olaparib for the Treatment of HER2-Negative Breast CancerAlexandra S. Zimmer, MD, staff clinician, Women's Malignancies Branch, National Cancer Institute Center for Cancer Research, discusses the promising data seen thus far with olaparib (Lynparza) for the treatment of HER2-negative breast cancer.
